Models of Palliative Care Delivery for Individuals with Cystic Fibrosis: Cystic Fibrosis Foundation Evidence-Informed Consensus Guidelines
- PMID: 32936045
- PMCID: PMC7757696
- DOI: 10.1089/jpm.2020.0311
Models of Palliative Care Delivery for Individuals with Cystic Fibrosis: Cystic Fibrosis Foundation Evidence-Informed Consensus Guidelines
Abstract
Cystic fibrosis (CF) affects more than 70,000 individuals and their families worldwide. Although outcomes for individuals with CF continue to improve, it remains a life-limiting condition with no cure. Individuals with CF manage extensive symptom and treatment burdens and face complex medical decisions throughout the illness course. Although palliative care has been shown to reduce suffering by alleviating illness-related burdens for people with serious illness and their families, little is known regarding the components and structure of various delivery models of palliative care needed to improve outcomes for people affected by CF. The Cystic Fibrosis Foundation (CFF) assembled an expert panel of clinicians, researchers, individuals with CF, and family caregivers, to develop consensus recommendations for models of best practices for palliative care in CF. Eleven statements were developed based on a systematic literature review and expert opinion, and address primary palliative care, specialty palliative care, and screening for palliative needs. These recommendations are intended to comprehensively address palliative care needs and improve quality of life for individuals with CF at all stages of illness and development, and their caregivers.
Keywords: clinical guidelines; cystic fibrosis; healthcare delivery; palliative care; patient-reported outcomes.
Conflict of interest statement
Dr. Dellon reports grants from Cystic Fibrosis Foundation, during the conduct of the study; Dr. Georgiopoulos reports nonfinancial support from Cystic Fibrosis Foundation, during the conduct of the study; grants, personal fees, and nonfinancial support from Cystic Fibrosis Foundation; and grants and personal fees from Vertex Pharmaceuticals, Inc., outside the submitted work. Dr. Goss reports grants from Cystic Fibrosis Foundation, grants from European Commission, grants from NIH (NHLBI), grants from NIH (NIDDK and NCRR), during the conduct of the study; personal fees from Gilead Sciences, personal fees from Novartis, grants from NIH, grants from FDA, other from Boehringer Ingelheim, and personal fees and nonfinancial support from Vertex, outside the submitted work. Mr. Hovater reports having received honoraria for other work with the Cystic Fibrosis Foundation unrelated to this article, outside the submitted work; Dr. McKinzie reports personal fees from Vertex Pharmaceuticals, Inc., outside the submitted work; Dr. Rabinowitz reports grants from Cystic Fibrosis Foundation First and Second Year Clinical Fellowship Training Grant Institutional Training Grant, RABI NO 1680, outside the submitted work. None of the work presented in this opinion piece was influenced by the funding sources noted above. The funding sources that support other ongoing research played no role in writing this article, or in the decision to submit for publication.
Figures


References
-
- Cystic Fibrosis Foundation: Cystic Fibrosis Foundation Patient Registry 2018 Annual Data Report. Bethesda, MD, 2019
-
- Marmor M, Jonas A, Mirza A, et al. : Opportunities to improve utilization of palliative care among adults with cystic fibrosis: A systematic review. J Pain Symptom Manage 2019;58:1100–1112 e1101. - PubMed
-
- Morrison RS, Meier DE: Palliative care. N Engl J Med 2004;350:2582–2590 - PubMed
-
- Quill TE, Abernethy AP: Generalist plus specialist palliative care—Creating a more sustainable model. N Engl J Med 2013;368:1173–1175 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical